Actisite

Tetracycline periodontal fibers are used to help treat periodontal disease (a disease of your gums). Periodontal disease is caused by bacteria growing beneath the gum line. Tetracycline works by keeping the number of bacteria from growing. Lowering the amount of bacteria helps to reduce inflammation and swelling in your mouth, and the amount of bleeding around the teeth. Tetracycline fibers are placed in the inflamed mouth areas by your dentist after he or she has thoroughly cleaned your teeth.

500 mg orally 4 times a day for 3 weeks given with streptomycin 1 g IM twice a day the first week and once a day the second week

500 mg orally every 6 hours for 21 to 30 days, depending on the nature and severity of the infection

500 mg orally every 6 hours for 7 to 10 days, depending on the nature and severity of the infection

500 mg orally 4 times a day for 7 days

The patient's sexual partner(s) should also be evaluated/treated.

Neisseria gonorrhoeae is insufficiently susceptible to tetracycline; therefore, tetracycline is not recommended by the CDC for the treatment of gonorrhea. Oral doxycycline therapy is the preferred treatment for possible concurrent chlamydial infection in nonpregnant patients.

500 mg orally every 6 hours for 3 to 7 days, depending on the nature and severity of the infection; recommended if no alternatives exist

Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses.

Some experts recommend:
CrCl 50 to 80 mL/min: Usual dose every 8 to 12 hours
CrCl 10 to 50 mL/min: Usual dose 12 to 24 hours
CrCl less than 10 mL/min: Usual dose every 24 hours

Data not available

Tetracycline may induce photosensitivity in some individuals. Patients on tetracycline therapy should minimize exposure to direct sunlight and other sources of ultraviolet radiation, and to use sunscreens and other protection whenever prolonged exposure is unavoidable. Therapy should be discontinued at the first sign of skin erythema.

If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated and, if therapy is prolonged, serum level determinations of the drug may be advisable.

Renal, hepatic, and hematopoietic function should be monitored periodically during prolonged therapy.

Decomposed tetracyclines may cause potentially fatal nephrotoxicity (Fanconi's syndrome); therefore, outdated or decomposed medications should be discarded.

Clostridium difficile associated diarrhea (CDAD) has been reported with almost all antibiotics and may potentially be life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea following tetracycline therapy. Mild cases generally improve with discontinuation of the drug, while severe cases may require supportive therapy and treatment with an antimicrobial agent effective against C difficile. Hypertoxin producing strains of C difficile cause increased morbidity and mortality; these infections can be resistant to antimicrobial treatment and may necessitate colectomy.

Data not available